Government of the United Kingdom   Report issue

Government Phase 1

Organization Overview

First Clinical Trial
2006
NCT00503022
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Alternative names

COREC,UK

Active Ingredients

Drugs in Phase 1 Trials (1)

canakinumab (ilaris) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Macular Degeneration (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1